Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 660

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 660
---
1,129,884 of such shares to satisfy certain additional liabilities of the closing date that may be identified after the closing. As additional Merger Consideration in the Mergers, Kineta stockholders will be entitled to receive their pro rata share of certain payments that Kineta may receive after the closing from the potential pre-closingsale by Kineta of certain non-KVA12123products and technologies. 441

NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

TuHURA and Kineta CTF Agreement

In connection with the New Merger Agreement, TuHURA and Kineta entered into a Clinical Trial Funding Agreement under which TuHURA agreed to
continue to fund clinical trial expenses for KVA12123 in an additional amount of up to $900,000, excluding the Existing Advances already financed, which may be increased upon mutual agreement. The Merger Agreement also provides that Kineta may
request the extension of additional working capital loans from TuHURA in increments of $250,000 on dates specified within the Merger Agreement; the last of which is to be advanced by TuHURA to Kineta on or before June 3, 2025, with that amount
being contingent upon TuHURA’s receipt of (A) proceeds from the Concurrent Investment or (B) proceeds from TuHURA’s stockholder warrant exercise payments due on May 30, 2025.

As of December 31, 2024, there had been no CTF Notes issued under the CTF Agreement; however, as of December 31, 2024 there were
four Existing Advances totaling $694,503. These Existing Advances represent advances already made by TuHURA to Kineta in connection with the exclusivity agreement and are included as a credit against the cash component of the Merger Consideration to
be paid to Kineta stockholders in the Mergers.

Through the date of this unaudited pro forma condensed combined financial information, the
total principal amount of CTF Notes funded under the CTF agreement was $851,809 (reflected within Pro Forma Adjustment A in Note 4 of the notes to the unaudited pro forma condensed combined financial information). Additionally, there have
been $750,000 of working capital loans made by TuHURA to Kineta subsequent to December 31, 2024, which is the expected amount that TuHURA will loan for Kineta’s working capital needs in increments of